Trial Profile
A pilot study of Taxotere [docetaxel] combined with Xeloda [capecitabine] in the treatment of metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Feb 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual end date (1 Jan 2006) added as reported by ClinicalTrials.gov.